Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML).
Vixtimotamab (TandAb T564; 24 h) induces CD25 and CD69 with EC50s of 1 pM and 2 pM, respectively[1]. Vixtimotamab (TandAb T564; 4 days) induces T-cell proliferation in PBMCs with an EC50 of 3 pM[1]. Vixtimotamab (TandAb T564; 25 pM, 48 h) shows cytotoxicity against HL-60 and KG-1a cells[1].
Vixtimotamab (TandAb T564; 0.1-10 μg/mouse, i.v.; 5 days) demonstrates dose-dependent tumor growth delay in a proplactic HL-60 graft NOD/scid mouse model[1].Vixtimotamab (TandAb T564; 50 μg/mouse/d, i.v.; 7 days) substantially inhibits tumor growth in an established HL-60 xenograft NOD/scid mouse model[1].
References:
[1]. Reusch U, et al. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res. 2016 Dec 1;22(23):5829-5838.